ГЕМОРРАГИЧЕСКИЙ СИНДРОМ В КЛИНИЧЕСКОЙ ПРАКТИКЕ

228.Markis M., Watson H.G. The management of coumarininduced overanticoagulation Br .J Haemotol. 2001; 114; 271 – 280.

229.McMinn J.L., George J.N. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J. Clin. Apheresis. 2001. 16(1): 202 – 9.

230.Menache D., Aronson D.L., Darr F., Montgomery R.R. et al. Pharmacokinetics of von Willebrandfactor and factor VIII: C in patients with severe von Willebrand disease (type 3) estimation of the rate of factor VIII: C synthesis. Brit. J. Haematol. 1996; 94: 740 – 745.

231.Moake J.L. Idiopathic thrombotic thrombocytopenia purpura/ in: Recent advances in thrombotic thrombocytopenic purpura// Hematology 2004: 407 – 423.

232.Montesinos P, Bergua JM, Vellenga E et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113: 775 – 783.

233.Monroe D.M., Hoffman M., Allen G.A., Roberts H.R. The factor VII – platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia // Semin. thrombosis and hemostasis. 2000. Vol. 26. P. 373 – 377.

234.Moscardo F., Perez F., De La Rubia J. et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII // British Journal of Haernatology. 2001. – Vol. 113. – P. 174 – 176.

235.Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease // Proc. N. Y. Pathol. Soc. – 1924. – 24: 21

– 24.

236.Muis W.A., Ratnoff O.D. The prevalence of plasma thromboplastin antecedent (PTA, Factor XI) deficiency. Blood. 1974; 44(4): 569 – 570.

237.Nee R., Doppenschmidt D., Donovan D.J., Andrews T.C. Intravenous versus subcutaneous vitamin K in reversing excessive oral anticoagulation. Am. J Cardiol.1999; 83: 286 – 288.

238.Nichols W.C., Ginsburg D. Von Willebrand disease. Medicine 1997; 76: 1 – 20.

239.Nillson I.M. Von Willebrand disease from 1926-1983. Scand. J. Haematol. 1984; 33, Suppl. 40: 21 – 43.

240.Nelson A.T., Hartzell J.D., More K., Durning S.J. Ingestion of superwarfarin leading to coagulopathy: a case report and review of the literature. MedGenMed. 2006; 8(4): 41.

241.O`Shaughnessy D.F., Atterbury C., Bolton Maggs P. et al.; British Commettee for Standards in Haemotology, Blood transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br .J Haemotol. 2004; 126(1): 11 – 28.

251

242.Osterman H ., Haertal S., Knaub S ., et al Pharmacokinetics of Beriplex P\N protrombin complex concentrates in healthy volunteers. Thromb. Haemost. 2007; 98: 790 – 797.

243.Owen C. Congenital deficiency of factor VII (hypoproconvertinemia). Amer. J. Med. 1964; 37(2): 71.

244.Pabinger I, Tiede A., Kalina U. et al impact of infusion speed on the safety and effectiveness of protrombin complex concentrate. Ann. Hematol. 2010; 89: 309 – 316.

245.Park BK, Choonara IA, Haynes BP, et al. Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. Br J Clin Pharmacol. 1986; 21: 289 – 293.

246.Perez-Sanchez I., Anguita J., Pintado T. Use of cyclophosphamide in treatment of thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus: report of two cases// Ann. Hematol. 1999; 78(6): 285 – 287.

247.Petersen D., Barthels M. Factitious disease caused by secret administration of the oral anticoagulant phenprocoumon: study of 16 personal cases. Med Klin (Munich). – 1995. – May. – 15 ; 90 (5) : 277 – 83.

248.Price PA. Role of vitamin-K-dependent proteins in bone metabolism, Annual Review of Nutrition, 1988, 8:565-83. Review. PMID: 3060178.

249.Quick AJ. The coagulation defect in sweet clover disease and in the haemorrhagic chick disease of dietary origin. Am J Physiol 1937; 112: 260 – 271.

250.Ragni M.V., Sinha D., Seaman F. et al. Comparison of bleeding tendency, factor XI coagulant activity and factor XI antigen in 25 factor XI-deficient kinder. Blood 1985; 65(3): 719 – 724.

251.Raj G., Kumar R., McKinney W.P. Time course of reversal of anticoagulant effect of warfarin by Intravenous and subcutaneous phytonadione Arch. Intern. Med. 1999; 159: 2721 – 2724.

252.Rapaport S.J., Proctor R.R., e.a. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 1961; 18(2): 149 - 165.

253.Remuzzi G., Galbusera M., Mannucci P.M. ADAMTS-13 in thrombotic microangiopathies. Blood 2002; 100(10): 3840 – 1.

254.Rimon A., Schiffman S., e.a. Factor XI activity and factor XI antigen in homozygous and heterozygous factor XI deficiency. Blood 1976; 48(2): 165 – 174.

255.Robeghiero F., Castman G., Mannucci P.M. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Trromb. Haemost. 1996; 76(5): 692 – 696.

256.Roberts H.R., Monroe D.M., Oliver J.A. et al. Newer concepts of blood coagulation // Haemophilia. 1998. – Vol. 4. – P. 331 – 334.

257.Roderick L.M. A problem in the coagulation of the blood; "sweet clover disease of the cattle". Am J Physiol 1931 96: 413 – 6.

252

258.Salzman S.W. Measurment of platelet aghesiveness, a simple in vitro technique demonstrating an abnormality in von Willebrand disease. J. Lab. Clin. Med. 1963; 62: 724 – 728.

259.Sacioglu Z., Aydogan G., Acici F. et al. rVIIA in our cases of coagenital factor VII deficiency / Turkish J. Haematol. 2005. V. 22. Suppl. Abstr. 343. P. 25.

260.Salzman S.W. Measurment of platelet aghesiveness, a simple in vitro technique demonstrating an abnormality in von Willebrand disease. J. Lab. Clin. Med. 1963; 62: 724 – 728.

261.Sane D.S., Streer N.R., Owen J. Myocardial necrosis in patients with thrombotic thrombocytopenic purpura: pathophysiology and rationale for specific therapy. Eur. J. Hematol. 2008; 82(2): 83 – 93.

262.Sarper N., Zengin E., Corapcioglu F. Successful tooth extraction with two doses of RFVIIA in a patient with Bernard-Soulier syndrome / Turkish J. Haematol. 2005. V. 22. Suppl. Abstr. 364. P. 363.

263.Savic I., Drosovic I., Popovic S. Use of recombinant factor VIIA (NovoSeven) in the treatment of patient with type I von Willebrand's disease with refractory gastrointestinal bleeding / Turkish J. Haematol. 2005. V. 22. Suppl. Abstr. 362. P. 163.

264.Schofield F.W. Damaged sweet clover; the cause of a new disease in cattle simulating haemorrhagic septicemia and blackleg. J Am Vet Med Ass 1924 64: 553 – 6.

265.Seligsohn U., Peyser M.R., Toaff R. et al. Severe hereditary deficiency of factor VII during pregnancy evidence for the absence of transplacental diffusion of factor VII. Thromb. Diathes. Haemorak. 1970; 24(1-2): 146 – 151.

266.Shua J.D., Friedenberg W.R Superwarfarin poisoning. Arch. Intern. Med. 1998:1929 – 1932.

267.Simsir I.Y., Sohin F., Sinetir A. et al. Effective use of high dose recombinant factor VIIA in the treatment of hemorrhagic cystitis induced by cyclophosphamide in a patient with CLL / Turkish J. Haematol. 2005. V. 22. Suppl. Abstr. 738. P. 303 – 304.

268.Smith L.G., Coone L.A.H., Kitchens C.S. Factor II (prothrombin) deficiency in identical twins. Clin. Res. 1979; 27 Abstr.: 745A.

269.Soria J., Soria C., Caen J.P. A new type of congenital dysfibrinogenemia with defective fibrin lysis-Dusard syndrome: possible relation to thrombosis. Brit. J. Haematol. 1983; 53(4): 575 – 586.

270.Spahr J.E., Maul J.S ., Rodgers J.M Superwarfarin poisoning: a report of two cases and review of literature . Am. J Haemotol. 2007;82: 656-660.

271.Stasi R., Pagano A., Stipa E. Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura // Blood, 2001; 98: 952 – 7.

272.Takeyama M., Sakurai Y., Shima M., et al. Heparin –incluced inhibitori effects of a prothrombin complex concentrate on global tests of haemostasis. Blood Coagul. 2007; 18: 1 – 7.

253

273.Tapon-Bretandiere J., Dumont M.D., Fischer A.-M. et al. Prothrombin Poissy: A new variant of human prothrombin. Thromb. Haemost. 1983; 50(1) Abstr. 0786: 250

274.Terrell D.R, Williams L.A., Vesely S.K. et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, end patients with severe ADAMTS-13 deficiency // J. Thromb. Haemost. 2005. 3(7): 1432 – 6.

275.Thompson C.E. et al. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic // Blood 1992; 80(8): 1890 – 1895.

276.Tsai H.-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion// Blood 1996; 87(10): 4235 – 4244.

277.Watson H.G., Baglin T., Laidlaw S.L et al. A comparison of the efficacy and rate response to oral and intravenous vitamin K in reversal of overanticoagulation with warfarin. Br .J Haemotol. 2001; 115; 145 – 149.

278.Watson W.A., Litovitz T.L., Rodgers G.C., et al. 2002 annual report of the American Association of Poison Control Centers, Toxic Exposure Surveillance System. Am J Emerg Med. 2003; 21: 353 – 421.

279.White B., McHale G., Ravi N. et al. Successful use of recombinant factor VIIa in the management of post-surgical intra-abdominal haemorrhage. Br.J.Haematol. 1999, 107 (3): 677 – 678.

280.White B., O'Connor H., Smith O. P. Successful use of recombinant Vila (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency // Blood Coagul. Fibrinolysis. 2000. Vol. 11 (2). P. 155 – 157.

281.West B.C. Chediak – Higashi syndrome neutrophils are characterized by the absence of both normal azurophilic granules. Amer. J. Pathol. 1986; 122(1): 177 – 189.

282.Wyrick-Glatzel J. Thrombotic thrombocytopenic purpura and ADAMTS-13: New insights into pathogenesis, diagnosis, and therapy // Lab. Med. 2004; 35(12): 733 – 740.

283.Yiu K.H, Siu C.W., Jim M.H., et al Compration of the efficacy and safety profiles of intravenous vitamin K and fresh frozen plasma as treatment of warfarin –related over anticoagulation in patients with mechanical heart valves . Am. J. Cardiol. 2006; 97 : 409 – 411.

284.Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365-1372.

285.Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes. Int J Hematol 2002; 75: 129 – 140.

286.Young NS, Scheinberg P, Calado T. Aplastic anemia. Curr Opin Hematol 2008; 15: 162 – 168.

254

287.Yuan S., Ferell C., Chandler W.L. Comparing the prothrombin time INR versus the APTT to evaluate the coagulopathy of acute trauma. Tromb. Res. 2007; 120: 29 – 37.

288.Zahner J., Schneider W. Munchausen syndrome in hematology: case reports of three variants and review of the literature. Ann Hematol. – 1994. Jun; 68

(6): 303 – 6.

289.Zafer S., Gönoül A., Akici F. et al. r VIIA use in our patients with glanzman thrombastenia / Turkish J. Haematol. 2005. V. 22. Suppl. Abstr. 353. P. 159–

160. Zhao S.L., Li P., Ji M., Zong Y., Zhang S.T. Upper gastrointestinal hemorrhage caused by superwarfarin poisoning. World J Gastroenterol 2010; 16(13): 1680 – 2.

290. Zupancic-Salek S., Kovacevic-Metelko J., Radman I.. Successful reversal of effect of anticoagulant superwarfarin poisoning with recombinant activated factor VII. Blood Coagul Fibrinolysis. 2005; 16: 239 – 44.

255